Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients

被引:32
作者
Morizio, Paige [1 ]
Burkhart, Jena I. [2 ]
Ozawa, Sachiko [1 ,3 ]
机构
[1] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[2] UNC Med Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
关键词
review article; osteoporosis; denosumab; bisphosphonates; cost-effectiveness; adherence; preference; WOMEN SUBOPTIMALLY ADHERENT; RANDOMIZED-OPEN-LABEL; LOW BONE MASS; POSTMENOPAUSAL OSTEOPOROSIS; UNITED-STATES; SATISFACTION; ALENDRONATE; MEDICATION; PREFERENCE; THERAPY;
D O I
10.1177/1060028018768808
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the cost-effectiveness as well as adherence and patient preference for denosumab compared with oral bisphosphonates for the treatment of osteoporosis. Data Sources: Two comprehensive PubMed literature searches (from data inception to December 2017) were performed. The first search included the terms osteoporosis, denosumab, bisphosphonate, and adherence or persistence or compliance or preference. The search terms osteoporosis, denosumab, cost, and effectiveness were used in the second literature search. Additional references were included from reviewing literature citations. Study Selection and Data Extraction: All English-language clinical trials on adherence (as compliance and persistence) or patient preference for denosumab compared with oral bisphosphonates were evaluated. In addition, articles analyzing the cost-effectiveness of denosumab compared with generic alendronate were evaluated. Data Synthesis: Four studies that assessed patient preference showed positive outcomes for preference and satisfaction for subcutaneous use of denosumab every 6 months versus oral alendronate weekly, oral ibandronate monthly, or oral risedronate monthly. Three studies evaluated persistence and compliance and/or adherence and showed improved persistence and compliance rates with denosumab compared with bisphosphonate therapy. Twelve articles and 3 abstracts assessed cost-effectiveness of denosumab compared with generic alendronate. The majority of articles showed that denosumab was cost-effective, and even cost-saving in patients older than 75 years of age and those who have a history of previous fractures, lower bone mineral density T-scores, and more risk factors. Conclusions: Denosumab compared with oral bisphosphonates may improve patient preference and adherence as well as provide a cost-effective treatment strategy, especially among higher-risk and older adults with osteoporosis.
引用
收藏
页码:1031 / 1041
页数:11
相关论文
共 43 条
[1]   CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS [J].
Albert, Stewart G. ;
Reddy, Supraja .
ENDOCRINE PRACTICE, 2017, 23 (07) :841-856
[2]   A COST-EFFECTIVENESS ANALYSIS OF DENOSUMAB FOR THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN GREECE [J].
Athanasakis, K. ;
Karampli, E. ;
Hollandezos, M. ;
Papagiannopoulou, V ;
Badamgarav, E. ;
Intorcia, M. ;
Kyriopoulos, J. .
VALUE IN HEALTH, 2011, 14 (07) :A308-A308
[3]   Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease [J].
Atkinson M.J. ;
Sinha A. ;
Hass S.L. ;
Colman S.S. ;
Kumar R.N. ;
Brod M. ;
Rowland C.R. .
Health and Quality of Life Outcomes, 2 (1)
[4]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[5]  
Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]
[6]   AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2016 [J].
Camacho, Pauline M. ;
Petak, Steven M. ;
Binkley, Neil ;
Clarke, Bart L. ;
Harris, Steven T. ;
Hurley, Daniel L. ;
Kleerekoper, Michael ;
Lewiecki, E. Michael ;
Miller, Paul D. ;
Narula, Harmeet S. ;
Pessah-Pollack, Rachel ;
Tangpricha, Vin ;
Wimalawansa, Sunil J. ;
Watts, Nelson B. .
ENDOCRINE PRACTICE, 2016, 22 :1-42
[7]  
Chau D, 2012, J Med Econ, V15 Suppl 1, P3, DOI 10.3111/13696998.2012.737393
[8]   Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States [J].
Cheng, Lung-I ;
Durden, Emily ;
Limone, Brendan ;
Radbill, Larry ;
Juneau, Paul L. ;
Spangler, Leslie ;
Mirza, Faisal M. ;
Stolshek, Bradley S. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (09) :824-U322
[9]   Clinician's Guide to Prevention and Treatment of Osteoporosis [J].
Cosman, F. ;
de Beur, S. J. ;
LeBoff, M. S. ;
Lewiecki, E. M. ;
Tanner, B. ;
Randall, S. ;
Lindsay, R. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (10) :2359-2381
[10]   COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL [J].
Cristino, J. ;
Canhao, H. ;
Perelman, J. ;
Santos, C. ;
Pereira, J. .
VALUE IN HEALTH, 2011, 14 (03) :A128-A128